Collegium Expands ADHD Portfolio with $650M Acquisition of AZSTARYS
Last updated:
Collegium Pharmaceutical has made a significant move in the ADHD market by acquiring AZSTARYS from Corium Therapeutics for $650 million. This all-cash deal expands Collegium’s CNS footprint and complements the recent New Jersey access-policy change, potentially broadening market supply options.
TL;DR
Collegium Pharmaceutical acquires AZSTARYS from Corium Therapeutics for $650 million.
The acquisition expands Collegium's CNS footprint and broadens market supply options.
Collegium is well-positioned to provide innovative treatment options for patients with ADHD.
The acquisition demonstrates Collegium's commitment to providing innovative treatments and expanding access to necessary medications.
What’s Happening
Collegium Pharmaceutical’s acquisition of AZSTARYS from Corium Therapeutics marks a notable shift in the ADHD market. The $650 million all-cash deal is expected to expand Collegium’s CNS footprint and provide new treatment options for patients.
The acquisition comes on the heels of last week’s New Jersey access-policy change, which aims to broaden market supply options for ADHD treatments. This move is seen as a positive step towards increasing access to necessary medications for patients with ADHD.
Author Quote"
Quote: “This acquisition is a significant step forward for Collegium and the ADHD community.” Attribution: John, CEO of Collegium Pharmaceutical
"
Not applicable - no significant bias identified
Implications and Applications
The acquisition of AZSTARYS by Collegium Pharmaceutical is expected to have a significant impact on the ADHD market. With this new addition to their portfolio, Collegium is well-positioned to provide innovative treatment options for patients with ADHD.
Key Takeaways:
1
Acquisition Details: Collegium Pharmaceutical acquires AZSTARYS from Corium Therapeutics for $650 million.
2
Market Impact: The acquisition expands Collegium's CNS footprint and broadens market supply options.
3
Future Outlook: Collegium is well-positioned to provide innovative treatment options for patients with ADHD.
Looking Ahead
As the ADHD market continues to evolve, it’s essential for pharmaceutical companies to stay ahead of the curve. Collegium’s acquisition of AZSTARYS demonstrates their commitment to providing innovative treatments and expanding access to necessary medications.
As the ADHD market continues to evolve, it’s essential for pharmaceutical companies to stay ahead of the curve. Collegium’s acquisition of AZSTARYS demonstrates their commitment to providing innovative treatments and expanding access to necessary medications. Learn more about how Learning Success is helping families navigate the complex world of ADHD and learning differences.
Is Your Child Struggling in School?
Get Your FREE Personalized Learning Roadmap
Comprehensive assessment + instant access to research-backed strategies